OF SHARED RESOURCE Since the founding of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Core (APC) in 1985, the primary mission of the APC has been to enable the inclusion of critical pharmacological endpoints in the design of clinical trials and preclinical studies, and stimulate new hypotheses and areas of investigation by providing by-cost, state-of-the-art services. The APC provides state-of-the-art equipment and facilities in 1200 square feet of laboratory space on the first floor of the SKCCC Cancer Research Building (CRBI). The location of the APC is adequate to meet the needs of the SKCCC investigators to investigate the pharmacokientics, pharmacodynamics, and pharmacogenetics of anticancer agents. Services include pharmacological trial design, analytical method development and validation, pharmacokinetic and pharmacodynamic data analysis and interpretation, and consultation for design of in vitro drug metabolism, protein binding studies, non-invasive phenotypic probes for drug metabolizing enzymes, and pharmacogenetic studies. The APC houses five UPLC/HPLC instruments with a UV/fluorescence (1), triple stage quadruple mass spectrometer (3), and a QTrap system with ion trap capabilities (1) for more intricate drug metabolism studies. The APC sample analysis has steadily increased since 2005 and is analyzing more than 4,000 samples/year with 20 new methods developed/year, serving over 26 faculty members who are members of eleven CCSG Programs with the majority of the users having peer-reviewed funding. The requested CCSG funding will support personnel who provide consultative services related to assay development, protocol design, and data interpretation, and who ensure that instrumentation is suitably maintained and available for investigators seeking support from the APC Lay: The ability to quantify drugs and their metabolites in cells, plasma, and tissues is an essential need in research aimed at determining how drugs go through the body and the link to the drug's effects both in animals and in humans. The Analytical Pharmacology Core laboratory provides services to design, conduct, and interpret this data. SKCCC Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-49
Application #
8559534
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-05-07
Project End
2017-04-30
Budget Start
2012-08-09
Budget End
2013-04-30
Support Year
49
Fiscal Year
2012
Total Cost
$182,687
Indirect Cost
$69,917
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications